Related references
Note: Only part of the references are listed.Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
David Baker et al.
EBIOMEDICINE (2017)
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Peter Alping et al.
ANNALS OF NEUROLOGY (2016)
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
Mika Komori et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Multiple sclerosis e-registries
Katharina Fink
NEURODEGENERATIVE DISEASE MANAGEMENT (2016)
The Swedish MS registry - clinical support tool and scientific resource
J. Hillert et al.
ACTA NEUROLOGICA SCANDINAVICA (2015)
Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Tomas Kalincik et al.
ANNALS OF NEUROLOGY (2015)
Comparative efficacy of switching to natalizumab in active multiple sclerosis
Timothy Spelman et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
Treating multiple sclerosis with monoclonal antibodies: a 2010 update
Mathias Buttmann
EXPERT REVIEW OF NEUROTHERAPEUTICS (2010)
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis - A 52-week phase II trial
R. T. Naismith et al.
NEUROLOGY (2010)
Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis
Orhan Aktas et al.
TRENDS IN NEUROSCIENCES (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2008)
Multiple sclerosis: new treatment trials and emerging therapeutic targets
Tracy DeAngelis et al.
CURRENT OPINION IN NEUROLOGY (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sensitivity analysis for m-estimates, tests, and confidence intervals in matched observational studies
Paul R. Rosenbaum
BIOMETRICS (2007)
Share Paper
